Saturday 17 October 2026
Export PRPH’s income statement to Excel — free account
ProPhase Labs, Inc.
PRPH Healthcare Diagnostics & Research
In the quarter to June 2026, revenue fell 18.9%, EPS grew 80.0%, free cash flow grew 56.7% and total debt rose 19.4%, each against the same quarter a year earlier.
0.01
0.00
0.00%
Follow PRPH
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
3.78 | 0.88 | 0.33 | 0.40 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(5.48) | (3.11) | (1.48) | (16.17) | |
P/B ratio |
2.79 | 1.09 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
4.08 | 2.19 | 2.04 | 2.19 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(1.94) | (1.14) | (1.21) | (1.25) | |
EV/FCF |
(1.95) | (1.16) | (1.23) | (1.25) | |
Quick Ratio |
0.07 | 0.03 | 0.03 | 0.03 | |
Current Ratio |
0.14 | 0.06 | 0.06 | 0.05 | |
Net Debt/EBITDA |
(0.55) | (4.26) | (4.99) | (6.13) | |
Debt/Assets |
2.92% | 9.68% | 9.97% | 9.88% | |
Debt/Equity |
0.28 | 1.65 | (9.54) | (1.82) | |
Asset Turnover |
0.06 | 0.07 | 0.06 | 0.06 | |
Operating CF/Net income |
0.51 | 0.17 | 0.14 | 0.03 | |
Capex/Depreciation |
0.00 | 0.00 | 0.01 | 0.00 | |
Interest Coverage |
(3.08) | (1.34) | (4.00) | (3.34) | |
Research and Development Expense of Revenue |
0.68% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
524.92% | 761.86% | 579.92% | 283.98% | |
Intangible Assets out of Total Assets |
0.18 | 0.19 | 0.18 | 0.17 | |
Share Based Compensation of Revenue |
48.81% | 55.23% | 81.59% | 37.09% | |
Graham Net Nets |
(2.67) | (13.93) | (50.73) | (45.76) | |
Graham Number |
0.00 | 0.00 | 1.92 | 3.45 | |
Earnings Yield |
(389.80%) | (386.58%) | (3,632.89%) | (2,655.11%) | |
Free Cash Flow Yield |
(55.22%) | (215.29%) | (508.06%) | (438.39%) | |
Revenue per Share |
0.21 | 0.09 | 0.04 | 0.07 | |
Operating CF per Share |
(0.84) | (0.14) | (0.06) | (0.01) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.84) | (0.14) | (0.06) | (0.01) | |
Cash per Share |
0.10 | 0.01 | 0.00 | 0.00 | |
Shareholders Equity per Share |
1.65 | 0.41 | (0.05) | (0.22) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.65 | 0.41 | (0.05) | (0.22) | |
Free Cash Flow |
(3.49) | (1.23) | (0.74) | (0.08) | |
Working Capital |
(47.51) | (49.93) | (52.99) | (55.28) | |
Capital Expenditures |
0.00 | 0.00 | 0.01 | 0.00 | |
Net Current Asset Value |
(51.07) | (53.21) | (56.23) | (57.72) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | (0.03) | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
17.46 | 10.80 | 10.87 | 10.81 | |
Average Payables |
28.65 | 27.14 | 27.53 | 29.20 | |
Average Inventory |
2.12 | 0.61 | 0.61 | 0.45 | |
Average Assets |
78.76 | 61.54 | 54.42 | 49.73 | |
Average Common Equity |
22.49 | 5.43 | 7.25 | 4.16 |
Columns are period end dates